• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Vibativ (telavancin)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Vibativ (telavancin)

  • Profile

Profile

Contact Information

Contact: Cumberland Pharmaceuticals
Website: https://vibativ.com/

Currently Enrolling Trials

    Show More

    Vibativ (telavancin) - 2 indications

    Scroll down for more information on each indication:

    • for the treatment of complicated skin and skin structure infections; approved September 2009
    • for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by staph aureus; approved June 2013

    General Information

    Vibativ (telavancin) is a bactericidal, once-daily, injectable lipoglycopeptide antibiotic with a dual mechanism of action whereby Vibativ both inhibits bacterial cell wall synthesis and disrupts bacterial cell membrane function.

    Vibativ is specifically indicated for the following:

    • for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), or Enterococcus faecalis (vancomycin-susceptible isolates only).
    • for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Staphylococcus aureus (including methicillin-susceptible and -resistant isolates). Vibativ should be reserved for use when alternative treatments are not suitable.

    Vibativ is supplied as a solution for intravenous infusion. The recommended dose is 10 mg/kg by IV infusion over 60 minutes every 24 hours for 7 to 14 days for cSSSI and for 7 to 21 days for HABP/VABP.

    Mechanism of Action

    Vibativ is a semisynthetic, lipoglycopeptide antibiotic. It inhibits bacterial cell wall synthesis by interfering with the polymerization and cross-linking of peptidoglycan. Telavancin binds to the bacterial membrane and disrupts membrane barrier function.

    Side Effects

    Adverse events associated with the use of Vibativ may include, but are not limited to, the following:

    • taste disturbance
    • nausea
    • vomiting
    • foamy urine
    • diarrhea
    • pruritus

    Indication 1 - for the treatment of complicated skin and skin structure infections

    approved September 2009

    Clinical Trial Results

    The FDA approval of Vibativ for cSSSI was based on two identical randomized, multinational, multicenter, double-blinded trials (Trial 1 and Trial 2) comparing Vibativ (10 mg/kg IV every 24 hours) with vancomycin (1 g 590 IV every 12 hours) for 7 to 14 days. The trials enrolled 1,794 adult subjects with cSSSI with suspected or confirmed MRSA as the primary cause of infection. Of the 1,794 enrolled subjects, 1,410 (78.6%) were clinically evaluable. The primary endpoint was non-inferiority in terms of the clinical cure rate at the follow-up test-of-cure visit. Results are from the clinically evaluable population: Trial One Vibativ: 84.3% and Vancomycin: 82.8%. Trial Two Vibativ: 83.9% and Vancomycin: 87.7%.

    Indication 2 - for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by staph aureus

    approved June 2013

    Clinical Trial Results

    The FDA approval of Vibativ for hospital-acquired and ventilator-associated pneumonia was based on two randomized, parallel-group, multinational, multicenter, double-blinded trials of identical design comparing Vibativ (10 mg/kg IV every 24 hours) with vancomycin (1 g IV every 12 hours) for 7 to 21 days. The subjects were premitted concomitant medication for gram-negative infections. All subjects had known or suspected infections due to methicillin-resistant Staphylococcus aureus. A total of 1,532 subjects were enrolled. The trials measured the percentage of subjects who died from any cause (all-cause mortality) 28 days after the initiation of treatment. Mortality rates were comparable between the Vibativ and vancomycin treatment arms, except for subjects who had pre-existing kidney problems. During clinical trials, more subjects with pre-existing kidney problems treated with Vibativ died compared to those treated with vancomycin.

    Approval Date: 2009-09-01
    Company Name: Cumberland Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing